Industry Verticals »

All Categories

Insights »

About TMR »

Short Bowel Syndrome Market Insights, 2021-2031

Short Bowel Syndrome Market (Product: Glucagon-like Peptide-2 [GLP2], Growth Hormone, Glutamine, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Patients with Short Bowel Syndrome at High Risk of Contracting Coronavirus

Patients with gastrointestinal (GI) diseases may be at increased risk for more severe illness due to the ongoing COVID-19 outbreak. Potential risk factors in these patients include their chronic inflammatory disease, comorbidities, and the use of glucocorticoids. Healthcare, being an essential industry, has compelled manufacturers in the short bowel syndrome market to maintain robust supply chains for treatment options and medicines to reduce morbidity and mortality rates.

The GI tract may be susceptible to coronavirus infection due to the widely expressed angiotensin-converting enzyme 2 (ACE2) receptors in the intestine. Hence, companies in the short bowel syndrome market are increasing the availability of products through online, hospital, and retail pharmacies to meet patient requirements and keep revenue streams flowing during the pandemic.

short bowel syndrome market infographic

Autologous Tissue Engineering Helps Overcome Challenges of Organ Transplant

Today, treating short bowel syndrome (SBS) requires long-term parenteral nutrition or an organ transplant. Since the outcome with the former treatment is uncertain, the latter is linked to the shortage of organs. Thus, researchers with the EU-funded INTENS project are striving to develop a better solution. Companies in the short bowel syndrome market are taking cues from such researchers to develop strategy for autologous tissue engineering, which is known as the process of treating an individual using their own cells or tissues.

The autologous tissue engineering strategy holds promising potentials to overcome the shortage of organs and avoid the need of the risky practice of suppressing the patient’s immune response.

Intravenous, Magnesium Supplements Improve Patient Quality of Life

The short bowel syndrome market is estimated to cross US$ 3.66 Bn by 2031. Apart from glucagon-like peptide-2 (GLP2) and growth hormones, companies are boosting their production capabilities in fish oil-based emulsions for patients suffering from intestinal failure-associated liver disease and liver cholestasis.

There is a growing demand for intravenous supplementation of fluids to maintain normal hydration and urinary flow for patients suffering from SBS. Manufacturers in the short bowel syndrome market are increasing efforts to meet this demand, since SBS patients suffer from complications such as dehydration, hyponatremia, and chronic renal failure. Since hypomagnesemia is caused by malabsorption of magnesium due to loss of the distal ileum, manufacturers are producing magnesium supplements to help patients achieve adequate hydration.

Oral Rehydration Products, Prescription Medicines Create Stable Revenue Sources

Nutritional support, medications, and surgery are the most preferred treatment options for SBS. Companies in the short bowel syndrome market are expanding their revenue streams in oral rehydration products including sports drinks and sodas without caffeine. Children are being recommended special drinks that contain salts and minerals such as Infalyte, CeraLyte, and Pedialyte, which are being made available at drug stores and grocery stores, to prevent dehydration.

Manufacturers in the short bowel syndrome market are establishing stable income sources through prescription medicines such as antibiotics, H2 blockers, proton pump inhibitors, and the likes to improve patient outcomes.

short bowel syndrome market segmentation

Analysts’ Viewpoint

Since patients with COVID-19 have reported gastrointestinal symptoms, such findings are creating additional revenue opportunities for manufacturers in the short bowel syndrome market. The short bowel syndrome market is expected to grow at a CAGR of 15.9% during the forecast period. However, the SBS treatment requires long-term parenteral nutrition or an organ transplant. Hence, companies should collaborate with researchers to increase the study in autologous tissue engineering, which helps in treating an individual using their own cells or tissues. Companies are boosting their output capacities in anti-secretin agents to help patients reduce gastric acid in the intestine, growth hormones, and hypomotility agents to increase the time it takes the food to travel through intestines, resulting in increased nutrient absorption.

Short Bowel Syndrome Market: Overview

  • According to Transparency Market Research’s latest report on the global short bowel syndrome market for the historical years 2017 and 2018 and forecast period of 2021–2031, rise in prevalence of short bowel syndrome, increase in demand for SBS drugs due to high cost of parenteral nutrition, and favorable reimbursement policies are projected to drive the global short bowel syndrome market during the forecast period
  • According to the report, the global short bowel syndrome market was valued at US$ 728.3 Mn in 2020 and is anticipated to expand at a CAGR of 15.9% from 2021 to 2031

High Cost of Parenteral Nutrition Increases Demand for SBS Drugs: Key Driver

  • Most of the short bowel syndrome patients are on parenteral nutrition initially until the patients’ intestine has adopted and hemostasis is being maintained. The cost of parenteral nutrition varies from patient to patient, and ranges between US$ 150,000 and US$ 586,000 per year. High cost of parenteral nutrition increases the demand for short bowel syndrome drugs, which have shown the ability to reduce patient’s dependence on parenteral nutrition during clinical trials.
  • For instance, apraglutide has the potential to enable patients to minimize the burden from parenteral support by increasing intestinal absorption of fluids, calories, and nutrients. Apraglutide has completed phase 2 studies and is currently being evaluated in a pivotal phase 3 clinical trial. Based on preclinical and clinical data to date, apraglutide has the potential to facilitate the treatment SBS-IF by establishing less frequent dosing and improving outcomes in a clinically meaningful fashion to address the needs of patients across the anatomical spectrum that characterizes the disease.

Rise in Prevalence of Short Bowel Syndrome to Boost Global Market

  • Prevalence of short bowel syndrome has risen across the globe in the past few years. This can be attributed to increase in the number of patients on total parenteral nutrition. The prevalence of short bowel syndrome is expected to be around four people per million, and the incidence is around three people per million.
  • The exact prevalence of the disease, however, is not clear, and it is estimated based on the number of people on parenteral nutrition. Rise in prevalence and incidence of the rare disease is likely to fuel the growth of the global market.
  • Approved drugs for the treatment of short bowel syndrome are not available globally and numerous other therapies are under clinical trials for the condition

High Cost of Treatment to Hamper Market

  • The cost of treatment of rare diseases is significantly high, which makes the treatment unaffordable for low-income groups. Additionally, lack of reimbursement in certain countries renders the treatment unreachable to several target group people.
  • In May 2019, the U.S. Food and Drug Administration (FDA) approved extending the indication of Gattex (teduglutide) for injection to pediatric patients 1 year of age and older with short bowel syndrome (SBS). Gattex (teduglutide) is an injectable drug used to treat adults with short bowel syndrome (SBS). Gattex is quite expensive, with treatment costing over US$ 295,000 a year.
  • The cost of treatment for the lifetime renders the treatment unaffordable, as rare diseases are life-threatening and do not have a permanent cure, thereby leading to a decline in the number of patients preferring to avail the treatment

Short Bowel Syndrome Market: Competition Landscape

  • This report profiles major players in the global short bowel syndrome market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • Leading players operating in the global short bowel syndrome market are
    • Takeda Pharmaceutical Company Limited
    • Merck KGaA
    • Zealand Pharma A/S
    • OxThera
    • VectivBio AG
    • 9 Meters Biopharma, Inc.
    • Nutrinia Ltd.
    • Hanmi Pharm.Co., Ltd.
    • Pharmascience, Inc.

Short Bowel Syndrome Market: Key Developments

  • Key players in the global short bowel syndrome market are engaged in regulatory approvals, development of new services, and acquisition & collaborative agreements with other companies. These strategies are likely to augment the global short bowel syndrome market over the next few years. A few expansion strategies adopted by players operating in the global short bowel syndrome market are:
    • In June 2021, VectivBio Holding AG announced that the FDA had granted orphan drug designation to Apraglutide, a next-generation, long-acting GLP-2 analog being developed for rare gastrointestinal (GI) diseases, for the prevention of acute graft-versus-host disease (aGVHD). GVHD is a severe, rare condition that can result from receiving an allogeneic hematopoietic stem cell transplant and the immune cells from the donor attack the patient’s healthy cells. VectivBio AG plans to initiate a phase 2 trial evaluating Apraglutide for the treatment of aGVHD in the first quarter of 2022.
    • In April 2021, Hanmi Pharm. Co. Ltd. announced that the U.S. Food and Drug Administration had granted fast-track designation to its short-bowel syndrome therapy, LAPS GLP-2 Analog (HM15912). LAPS GLP-2 Analog is a new biopharmaceutical being developed for short-bowel syndrome with the company's platform technology, known as Labscovery. The disorder occurs in about 24.5 out of 100,000 newborns and severely affects children and adolescents' growth, with a survival rate under 50%.
    • In December 2020, 9 Meters Biopharma, Inc. announced positive topline results from its open-label phase 1b/2a clinical trial evaluating NM-002, its proprietary long-acting glucagon-like peptide-1 (GLP-1) receptor agonist in adults with short bowel syndrome (SBS). NM-002 is designed as a long-acting injectable GLP-1 receptor agonist that utilizes proprietary XTEN technology to extend circulating half-life. This is designed specifically to slow digestive transit time in SBS patients by reducing upper GI motility and improve the chronic diarrhea associated with a shortened intestine.
    • On April 30 2020, 9 Meters Biopharma, Inc. completed merger with privately held RDD Pharma, Ltd., an Israel-based corporation (“RDD”) (the “RDD Merger”) and changed its name from Innovate Biopharmaceuticals, Inc. to 9 Meters Biopharma, Inc.
    • In May 2019, the U.S. Food and Drug Administration (FDA) approved extending the indication of GATTEX (teduglutide) for injection to pediatric patients 1 year of age and older with short bowel syndrome (SBS) who need additional nutrition or fluids from intravenous (IV) feeding (parenteral support
    • On January 2019, Takeda Pharmaceutical Company Limited completed the acquisition of Shire plc, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Post the acquisition, Takeda has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly innovative medicines to around 80 countries/regions with dedicated employees across the world
  • The report on the global short bowel syndrome market discussed individual strategies, followed by company profiles. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global short bowel syndrome market.

Frequently Asked Questions

What is the total market worth of short bowel syndrome market?

Short bowel syndrome market is estimated to cross US$ 3.66 Bn by 2031

What is the anticipated CAGR of the short bowel syndrome market in the forecast period?

Short bowel syndrome market is projected to expand at a CAGR of 15.9% from 2021 to 2031

What are the key driving factors for the growth of the short bowel syndrome market?

Short bowel syndrome market is driven by rise in prevalence of short bowel syndrome, increase in demand for SBS drugs due to high cost of parenteral nutrition, and favorable reimbursement policies

Which is the rising prominent segment in the short bowel syndrome market?

The glucagon-like peptide-2 segment dominated the global short bowel syndrome market in 2020, and the trend is projected to continue during the forecast period

Who are the key players in the global short bowel syndrome market?

Key players in the global short bowel syndrome market include Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma, Inc., Nutrinia Ltd., Hanmi Pharm.Co., Ltd., and Pharmascience, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Short Bowel Syndrome Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Short Bowel Syndrome Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Short Bowel Syndrome: Disease Overview

    5.2. Pipeline Analysis & Clinical Trials Analysis

    5.3. Disease Prevalence & Incidence Rate, Globally with Key Regions

    5.4. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)

    5.5. COVID-19 Pandemic Impact on Industry

6. Global Short Bowel Syndrome Market Analysis and Forecast, by Product

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value & Volume Forecast, by Product, 2017–2031

        6.3.1. Glucagon-like Peptide-2 (GLP2)

        6.3.2. Growth Hormone

        6.3.3. Glutamine

        6.3.4. Others

    6.4. Market Attractiveness Analysis, by Product

7. Global Short Bowel Syndrome Market Analysis and Forecast, by Distribution Channel

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value & Volume Forecast, by Distribution Channel, 2017–2031

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Sales

    7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Short Bowel Syndrome Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value & Volume Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Japan

        8.2.4. Australia

        8.2.5. Rest Of World

    8.3. Market Attractiveness Analysis, by Country/Region

9. North America Short Bowel Syndrome Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value & Volume Forecast, by Product, 2017–2031

        9.2.1. Glucagon-like Peptide-2 (GLP2)

        9.2.2. Growth Hormone

        9.2.3. Glutamine

        9.2.4. Others

    9.3. Market Value & Volume Forecast, by Distribution Channel, 2017–2031

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Sales

    9.4. Market Value & Volume Forecast, by Country, 2017–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Product

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Short Bowel Syndrome Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value & Volume Forecast, by Product, 2017–2031

        10.2.1. Glucagon-like Peptide-2 (GLP2)

        10.2.2. Growth Hormone

        10.2.3. Glutamine

        10.2.4. Others

    10.3. Market Value & Volume Forecast, by Distribution Channel, 2017–2031

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Sales

    10.4. Market Value & Volume Forecast, by Country/Sub-Region, 2017–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Product

        10.5.2. By Distribution Channel

        10.5.3. By Country/Sub-Region

11. Japan Short Bowel Syndrome Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value & Volume Forecast, by Product, 2017–2031

        11.2.1. Glucagon-like Peptide-2 (GLP2)

        11.2.2. Growth Hormone

        11.2.3. Glutamine

        11.2.4. Others

    11.3. Market Value & Volume Forecast, by Distribution Channel, 2017–2031

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Sales

    11.4. Market Attractiveness Analysis

        11.4.1. By Product

        11.4.2. By Distribution Channel

12. Australia Short Bowel Syndrome Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value & Volume Forecast, by Product, 2017–2031

        12.2.1. Glucagon-like Peptide-2 (GLP2)

        12.2.2. Growth Hormone

        12.2.3. Glutamine

        12.2.4. Others

    12.3. Market Value & Volume Forecast, by Distribution Channel, 2017–2031

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Sales

    12.4. Market Attractiveness Analysis

        12.4.1. By Product

        12.4.2. By Distribution Channel

13. Rest Of World Short Bowel Syndrome Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value & Volume Forecast, by Product, 2017–2031

        13.2.1. Glucagon-like Peptide-2 (GLP2)

        13.2.2. Growth Hormone

        13.2.3. Glutamine

        13.2.4. Others

    13.3. Market Value & Volume Forecast, by Distribution Channel, 2017–2031

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Sales

    13.4. Market Attractiveness Analysis

        13.4.1. By Product

        13.4.2. By Distribution Channel

14. Competition Landscape

    14.1. Market Player – Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis By Company (2020)

    14.3. Company Profiles

        14.3.1. Takeda Pharmaceutical Company Limited

            14.3.1.1. Company Description

            14.3.1.2. Business Overview

            14.3.1.3. Financial Overview

            14.3.1.4. Strategic Overview

            14.3.1.5. SWOT Analysis

        14.3.2. Merck KGaA

            14.3.2.1. Company Description

            14.3.2.2. Business Overview

            14.3.2.3. Financial Overview

            14.3.2.4. Strategic Overview

            14.3.2.5. SWOT Analysis

        14.3.3. Zealand Pharma A/S

            14.3.3.1. Company Description

            14.3.3.2. Business Overview

            14.3.3.3. Financial Overview

            14.3.3.4. Strategic Overview

            14.3.3.5. SWOT Analysis

        14.3.4. OxThera

            14.3.4.1. Company Description

            14.3.4.2. Business Overview

            14.3.4.3. Financial Overview

            14.3.4.4. Strategic Overview

            14.3.4.5. SWOT Analysis

        14.3.5. VectivBio AG

            14.3.5.1. Company Description

            14.3.5.2. Business Overview

            14.3.5.3. Financial Overview

            14.3.5.4. Strategic Overview

            14.3.5.5. SWOT Analysis

        14.3.6. 9 Meters Biopharma, Inc.

            14.3.6.1. Company Description

            14.3.6.2. Business Overview

            14.3.6.3. Financial Overview

            14.3.6.4. Strategic Overview

            14.3.6.5. SWOT Analysis

        14.3.7. Nutrinia Ltd.

            14.3.7.1. Company Description

            14.3.7.2. Business Overview

            14.3.7.3. Financial Overview

            14.3.7.4. Strategic Overview

            14.3.7.5. SWOT Analysis

        14.3.8. Hanmi Pharm Co., Ltd.

            14.3.8.1. Company Description

            14.3.8.2. Business Overview

            14.3.8.3. Financial Overview

            14.3.8.4. Strategic Overview

            14.3.8.5. SWOT Analysis

        14.3.9. Pharmascience, Inc.

            14.3.9.1. Company Description

            14.3.9.2. Business Overview

            14.3.9.3. Financial Overview

            14.3.9.4. Strategic Overview

            14.3.9.5. SWOT Analysis

List of Tables

Table 01: Global Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 02: Global Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 03: Global Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 05: North America Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 06: North America Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 07: Europe Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 08: Europe Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 09: Europe Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 10: Japan Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 11: Japan Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: Australia Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 13: Australia Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 14: Rest of the World Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 15: Rest of the World Short Bowel Syndrome Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Short Bowel Syndrome Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Short Bowel Syndrome Market Value Share, by Product, 2020

Figure 03: Short Bowel Syndrome Market Value Share, by Distribution Channel, 2020

Figure 04: Global Short Bowel Syndrome Market Value Share Analysis, by Product, 2020 and 2031

Figure 05: Global Short Bowel Syndrome Market Attractiveness Analysis, by Product, 2021–2031

Figure 06: Global Short Bowel Syndrome Market Revenue (US$ Mn), by Glucagon-like Peptide-2 (GLP2), 2017–2031

Figure 07: Global Short Bowel Syndrome Market Revenue (US$ Mn), by Growth Hormone, 2017–2031

Figure 08: Global Short Bowel Syndrome Market Revenue (US$ Mn), by Glutamine, 2017–2031

Figure 09: Global Short Bowel Syndrome Market Revenue (US$ Mn), by Others, 2017–2031

Figure 10: Global Short Bowel Syndrome Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 11: Global Short Bowel Syndrome Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 12: Global Short Bowel Syndrome Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031

Figure 13: Global Short Bowel Syndrome Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

Figure 14: Global Short Bowel Syndrome Market Revenue (US$ Mn), by Online Sales, 2017–2031

Figure 15: Global Short Bowel Syndrome Market Value Share Analysis, by Region, 2020 and 2031

Figure 16: Global Short Bowel Syndrome Market Attractiveness Analysis, by Region, 2021–2031

Figure 17: North America Short Bowel Syndrome Market Value (US$ Mn) Forecast, 2017–2031

Figure 18: North America Short Bowel Syndrome Market Value Share Analysis, by Country, 2020 and 2031

Figure 19: North America Short Bowel Syndrome Market Attractiveness Analysis, by Country, 2021–2031 

Figure 20: North America Short Bowel Syndrome Market Value Share Analysis, by Product, 2020 and 2031

Figure 21: North America Short Bowel Syndrome Market Attractiveness Analysis, by Product, 2021–2031

Figure 22: North America Short Bowel Syndrome Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 23: North America Short Bowel Syndrome Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 24: Europe Short Bowel Syndrome Market Value (US$ Mn) Forecast, 2017–2031

Figure 25: Europe Short Bowel Syndrome Market Value Share Analysis, by Country/Sub-Region, 2020 and 2031

Figure 26: Europe Short Bowel Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 27: Europe Short Bowel Syndrome Market Value Share Analysis, by Product, 2020 and 2031 

Figure 28: Europe Short Bowel Syndrome Market Attractiveness Analysis, by Product, 2021–2031

Figure 29: Europe Short Bowel Syndrome Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 30: Europe Short Bowel Syndrome Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 31: Japan Short Bowel Syndrome Market Value (US$ Mn) Forecast, 2017–2031

Figure 32: Japan Short Bowel Syndrome Market Value Share Analysis, by Product, 2020 and 2031

Figure 33: Japan Short Bowel Syndrome Market Attractiveness Analysis, by Product, 2021–2031

Figure 34: Japan Short Bowel Syndrome Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 35: Japan Short Bowel Syndrome Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 36: Australia Short Bowel Syndrome Market Value (US$ Mn) Forecast, 2017–2031

Figure 37: Australia Short Bowel Syndrome Market Value Share Analysis, by Product, 2020 and 2031

Figure 38: Australia Short Bowel Syndrome Market Attractiveness Analysis, by Product, 2021–2031

Figure 39: Australia Short Bowel Syndrome Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 40: Australia Short Bowel Syndrome Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Figure 41: Rest of the World Short Bowel Syndrome Market Value (US$ Mn) Forecast, 2017–2031

Figure 42: Rest of the World Short Bowel Syndrome Market Value Share Analysis, by Product, 2020 and 2031

Figure 43: Rest of the World Short Bowel Syndrome Market Attractiveness Analysis, by Product, 2021–2031

Figure 44: Rest of the World Short Bowel Syndrome Market Value Share Analysis, by Distribution Channel, 2020 and 2031

Figure 45: Rest of the World Short Bowel Syndrome Market Attractiveness Analysis, by Distribution Channel, 2021–2031

Copyright © Transparency Market Research, Inc. All Rights reserved

Short Bowel Syndrome Market Insights, 2021-2031

Schedule a Call